| Name | Title | Contact Details |
|---|
Savara Inc. is an orphan lung disease company. Savara`s pipeline comprises: Molgradex, an inhaled granulocyte-macrophage colony-stimulating factor, or GM-CSF, in Phase 3 development for PAP, and in Phase 2a development for NTM lung infection; and AeroVanc, a Phase 3 stage inhaled vancomycin for treatment of MRSA infection in cystic fibrosis. Savara`s strategy involves expanding its pipeline of potentially best-in-class products through indication expansion, strategic development partnerships and product acquisitions, with the goal of becoming a leading company in its field. Savara`s management team has significant experience in orphan drug development and pulmonary medicine, in identifying unmet needs, developing and acquiring new product candidates, and effectively advancing them to approvals and commercialization.
Cadista utilizes vertical integration - from base chemicals to final distribution. Increasingly, it focuses on relevant extended and immediate release oral solid products to deliver high value to the global marketplace. The company has maintained a
ABL Medical, LLC
The Abacus Medicine Group creates better access to medicine. We help life-critical medicines become more widely available.